UPCOMING SESSIONS in ET
Thu, Sep 3, 2026
5:00 – 6:00 AM Bangkok
How I treat AL Amyloidosis: Emerging Therapies Angela Dispenzieri Click Here To Register
UPCOMING SESSIONS in ET
Thu, Sep 3, 2026 · 5:00 – 6:00 AM Bangkok
How I treat AL Amyloidosis: Emerging Therapies
Angela Dispenzieri
Click Here To Register
View all sessions

Amyloidosis: What Every Physician Needs to Know

Key Information
Source
Decision Support in Medicine
summary/abstract
Amyloidosis is a term for diseases caused by extracellular deposition of protein fibrils. The accepted nomenclature is "AX", "A" for amyloidosis, and "X" indicating the precursor protein. If the precursor is an immunoglobulin light chain, the disease is termed AL, the most common of the systemic amyloidoses. If it is familial (AF), the precursor protein can be an inherited mutant serum protein such as transthyretin, abbreviated ATTR, or proteins such as lysozyme, fibrinogen, gelsolin, or apolipoproteins.
The old nomenclature of "primary" and "secondary" is no longer used, although AA amyloidosis, involving formation of fibrils from serum amyloid A (SAA) protein, is truly secondary to chronic inflammatory or infectious states, as SAA is an acute phase reactant.
Abstract Source
https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/hematology/amyloidosis/
Authors
David Seldin